Pfizer Inc. $PFE Shares Sold by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 23.8% in the 4th quarter, Holdings Channel reports. The fund owned 62,795 shares of the biopharmaceutical company’s stock after selling 19,641 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $1,564,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Franklin Resources Inc. lifted its stake in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Vanguard Group Inc. lifted its stake in shares of Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. Neuberger Berman Group LLC lifted its stake in shares of Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after purchasing an additional 6,045,763 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after purchasing an additional 5,978,927 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Pfizer by 120.9% in the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after purchasing an additional 5,202,884 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. Royal Bank Of Canada reiterated an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. UBS Group raised their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Monday, April 13th. HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $28.61.

Pfizer Stock Performance

NYSE:PFE opened at $25.92 on Tuesday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a 50-day moving average price of $26.84 and a two-hundred day moving average price of $26.25. Pfizer Inc. has a twelve month low of $22.88 and a twelve month high of $28.75. The company has a market capitalization of $147.72 billion, a P/E ratio of 19.79 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm posted $0.92 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.